Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®)

Assessment Status Assessment Process Complete
Drug Nivolumab
Brand Opdivo®
Indication Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC) for RCC.
Assessment Process
Rapid review commissioned 28/11/2018
Rapid review completed 11/12/2018
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 19/12/2018
Pre-submission consultation with Applicant 28/01/2019
Full submission received from Applicant 01/04/2019
Preliminary review sent to Applicant 23/09/2019
NCPE assessment re-commenced 21/10/2019
Factual accuracy sent to Applicant 28/11/2019
NCPE assessment re-commenced 06/12/2019
NCPE assessment completed 07/01/2020
NCPE assessment outcome The NCPE recommends that nivolumab in combination with ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations February 2021.